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A multidrug-resistant Stenotrophomonas maltophilia 




Stenotrophomonas maltophilia is a significant opportunistic pathogen that is associated with high mortality in immunocompromised 
individuals. In this study, we describe a multidrug-resistant (MDR) S. maltophilia clinical isolate from Kamuzu Central Hospital (KCH), 
Lilongwe, Malawi. 
Methods
A ceftriaxone and meropenem nonsusceptible isolate (Sm-MW08), recovered in December 2017 at KCH, was referred to the 
National Microbiology Reference Laboratory for identification. In April 2018, we identified the isolate using MALDI Biotyper mass 
spectrometry and determined its antimicrobial susceptibility profile using microdilution methods. Sm-MW08 was analysed by S1- 
PFGE, PCR, and Sanger sequencing, in order to ascertain the genotypes that were responsible for the isolate`s multidrug-resistance 
(MDR) phenotype. 
Results
Sm-MW08 was identified as S. maltophilia and exhibited resistance to a range of  antibiotics, including all β-lactams, aminoglycosides 
(except arbekacin), chloramphenicol, minocycline, fosfomycin and fluoroquinolones, but remained susceptible to colistin and 
trimethoprim-sulfamethoxazole. The isolate did not harbour any plasmid but did carry chromosomally-encoded blaL1 metallo-β-
lactamase and blaL2 β-lactamase genes; this was consistent with the isolate’s resistance profile. No other resistance determinants were 
detected, suggesting that the MDR phenotype exhibited by Sm-MW08 was innate.
Conclusion
Herein, we have described an MDR S. maltophilia from KCH in Malawi, that was resistant to almost all locally available antibiotics. We 
therefore recommend the practice of  effective infection prevention measures to curtail spread of  this organism.
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Introduction
Reports of  multidrug-resistant (MDR) bacteria have 
dramatically increased, posing a threat to medical 
interventions. One such organism is Stenotrophomonas 
maltophilia, a significant opportunistic pathogen that can be 
fatal in immunocompromised individuals. This organism is 
associated with mortality rates as high as 69% in systemic 
infections1. The World Health Organization (WHO) has 
listed S. maltophilia as one of  the emerging pathogens that 
are of  importance to public health2. This gram-negative 
bacterium is usually inherently resistant to some common 
antibiotics3 but can acquire additional resistance horizontally, 
ultimately rendering almost all antibiotics ineffective3. 
In Malawi, ceftriaxone, sulfamethoxazole-trimethoprim, 
aminoglycosides, and fluoroquinolones, are the most 
commonly used antibiotics to treat gram-negative bacterial 
infections. In this report, we describe an MDR S. maltophilia 
isolate from Kamuzu Central Hospital (KCH) in Lilongwe, 
Malawi. We also provide an antimicrobial susceptibility 
profile to inform us of  potential therapeutic options for 
treating infections caused by this isolate. 
Methods
A ceftriaxone and meropenem nonsusceptible gram-negative 
bacillus (designated Sm-MW08) was recovered at KCH 
from a blood sample taken from a patient admitted to the 
medical ward high-dependency unit in December 2017. The 
isolate was submitted to the Malawi National Microbiology 
Reference Laboratory (MNMRL) for identification and 
further microbiological investigation. Sm-MW08 was 
anonymized at KCH laboratory prior to submission. In 
April 2018, we revived the isolate from a glycerol stock 
using brain heart infusion (BHI) agar and identified it 
by mass spectrometry using a MALDI Biotyper system 
(Bruker Daltonics GmbH, Leipzig, Germany). Profiling 
of  the antimicrobial susceptibility pattern of  Sm-MW08 
was performed by determining the minimum inhibitory 
concentrations (MICs) of  various antibiotics using the 
MicroScan WalkAway Plus system (Beckman Coulter, CA, 
USA) or Eiken dry plates (Eiken, Tokyo, Japan). Results 
were interpreted according to CLSI version M100-S24 or 
EUCAST version 9.0 guidelines.
Since Sm-MW08 initially exhibited nonsusceptibility to 
meropenem and ceftriaxone, we screened the isolate for 
carbapenemases (these confer resistance to almost all β-lactam 
antibiotics) using the modified carbapenem inactivation 
method according to the CLSI protocol. We also tested the 
isolate for the production of  extended-spectrum β-lactamases 
(using cefotaxime + clavulanic acid); these enzymes confer 
resistance to aztreonam and oxyimino-cephalosporins (e.g., 
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Figure 1: Antimicrobial susceptibility profile of S. maltophilia Sm-MW08 clinical isolate recovered at Kamuzu Central 
Hospital, Malawi. All results were interpreted using CLSI version M100-S24 guidelines except for colistin which was 
interpreted using EUCAST version 9.0 guidelines and arbekacin which was defined based on previous reports. MIC, 
minimum inhibitory concentration.
Figure 2: S. maltophilia Sm-MW08 harboured both blaL1 metallo-ᵦ-lactamase and blaL2 ᵦ-lactamase genes. Bacterial DNA was extracted using PowerSoil DNA isolation kit (Qiagen) followed by a multiplex PCR using Ex-Taq DNA polymerase (TaKaRa) at 
98 °C initial denaturation for 3 min, 35 cycles of 98 °C denaturation for 30 s, 60°C annealing for 30 s and 72°C extension for 40 
s. PCR products were analysed by Electrophoresis on a 2% gel. Primer sequences were designed during this study.
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cefotaxime, ceftazidime and ceftriaxone). We also used PCR 
to screen Sm-MW08 for carbapenemase-encoding genes 
(blaNDM, blaKPC, blaOXA-48-Like, and blaL1) and other β-lactamase 
genes (blaCTX-M, blaSHV, blaTEM, and blaL2). Next, we used PCR 
and Sanger sequencing to screen Sm-MW08 for mutations 
within the quinolone resistance determining region (QRDR); 
this region is known to confer quinolone/fluoroquinolone 
resistance. Finally, to investigate the possibility of  acquired 
resistance, we analysed Sm-MW08 for plasmids by S1 pulsed-
field gel-electrophoresis (PFGE).
Results
Sm-MW08 was identified as S. maltophilia. The isolate was 
resistant to almost all of  the antibiotics tested, including 
all β-lactams (including meropenem and β-lactamase 
inhibitor combinations), gentamicin, amikacin, minocycline, 
ciprofloxacin, levofloxacin, fosfomycin, and chloramphenicol, 
but remained susceptible to arbekacin, sulfamethoxazole-
trimethoprim, and colistin (Figure 1). PCR revealed that 
Sm-MW08 harboured blaL1 metallo-β-lactamase and blaL2 
β-lactamase (Figure 2); these findings were confirmed by 
Sanger sequencing. The hydrolytic activities of  L1 and L2 
were confirmed by disc inactivation and double disc tests, 
respectively. We did not detect any plasmids in S. maltophilia 
Sm-MW08 or any other resistance determinants or mutations 
within the QRDR.
Discussion
MDR S. maltophilia is an emerging pathogen that can cause life-
threatening infections in immunocompromised individuals. 
S. maltophilia Sm-MW08 was recovered from a bacteraemic 
patient at KCH. The isolate exhibited resistance to almost 
all tested antibiotics, but remained susceptible to one 
locally available antibiotic, sulfamethoxazole-trimethoprim; 
this is a recognized drug option for the treatment of  S. 
maltophilia infections.3,4. However, bacteria with plasmid-
encoded sulfamethoxazole-trimethoprim resistance genes 
are prevalent in Malawi and the subsequent acquisition of  
these genes by this isolate could limit the treatment options 
available. 
Sm-MW08 exhibited resistance to all β-lactam antibiotics and 
to β-lactamase inhibitors (Figure 1); this was consistent with 
the co-presence of  chromosomally-encoded L1 metallo-
β-lactamase and L2 serine-β-lactamase. We consider that 
the resistance to other antibiotics, such as aminoglycosides, 
fluoroquinolones, and fosfomycin, was presumably due 
to low membrane permeability and/or derepression of  
chromosomally encoded multidrug resistance efflux pumps, 
as previously reported5. Notably, Sm-MW08 was devoid of  a 
plasmid, further suggesting that the MDR-phenotype in Sm-
MW08 was innate. Remarkably, S. maltophilia has been isolated 
from various hospital devices and can survive in various 
nutrient-poor environments (such as bottled water and hand-
washing soap)3, thus making S. maltophilia a significant issue 
of  concern in clinical settings. Previous research found that 
antimicrobial susceptibility profiles vary between clinical and 
environmental isolates of  S. maltophilia3, thus highlighting 
the need for susceptibility testing to guide the appropriate 
selection of  antibiotics. S. maltophilia is commonly associated 
with immuno-incompetence; however, no clinical data were 
available for the patient at the time this study was carried out. 
Nevertheless, the recovery of  this clinical isolate at KCH is 
of  significant clinical importance.
Conclusion
We have described an MDR S. maltophilia isolate from Malawi. 
The isolate was resistant to almost all antibiotics tested. We 
therefore, recommend the implementation and practice of  
effective infection prevention measures to curtail the spread 
of  this isolate. 
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